

Evonik partners with Jland Biotech to market vegan collagen for cosmetic applications

- Investment from Evonik's Venture Capital group in Jland
- Meets high market demand for vegan collagen for cosmetic and personal care applications
- Next strategic step to expand Evonik's collagen platform

Essen, Germany. Evonik is partnering with the Chinese company Jland Biotech to market vegan collagen for cosmetic and personal care applications. To maximize the benefits from a long-term, robust partnership, Evonik has invested in Jland Biotech through its Venture Capital group. The partnership will enable Evonik to provide commercial quantities of collagen for applications in skincare such as anti-aging and hydrating creams. The new collagen products, manufactured in collaboration with Jland, will be launched later this year, expanding Evonik's existing product portfolio of vegan collagen. Evonik recently launched its own vegan collagen Vecollage™ Fortify L for cosmetic and personal care applications.

"Evonik's life sciences division is using its biotechnology platform to leverage the expertise of its partners and collaborate on precision biosolutions. We welcome Jland to our partner network," said Johann-Caspar Gammel, President of the Nutrition & Care division. "Together with our expertise in active ingredients and delivery systems, we are creating a world-leading portfolio of non-animal derived collagen."

"We value Jland's outstanding approach to innovation and look forward to helping our customers develop the science-based, sophisticated beauty solutions that consumers worldwide are looking for," said Yann d'Hervé, Head of Evonik's Care Solutions business line.

Collagen can be used as a bioactive in cosmetic and personal care applications to improve elasticity and hydration in the skin. Global trends towards sustainability is driving a demand for dermatological solutions with high concentrations of active ingredients. Vegan collagen is of particular interest for

22 February 2024

Main press contact

Jana Flommersfeld

Head of Market Communications
Care Solutions
Phone + 49 201 173-3772
jana.flommersfeld@evonik.com

Alternative press contact

Dr. Jürgen Krauter

Head of Market Communications Evonik
Phone +49 6181 59-6847
juergen.krauter@evonik.com

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
www.evonik.com

Supervisory Board

Bernd Tönjes, Chairman

Executive Board

Christian Kullmann, Chairman

Dr. Harald Schwager, Deputy Chairman

Maike Schuh, Thomas Wessel

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

formulators developing cosmeceuticals – cosmetic products and bioactive ingredients that are effective in the deep layers of the skin and cater to the rising number of consumers following sophisticated skin regimens.

Jland Biotech is a company dedicated to developing and manufacturing non-animal-derived collagen. It was founded in 2015 and has its headquarters in Jingjiang, China. Jland's core technology is centred around a production process that seamlessly incorporates efficiency and scalability. It develops collagen with multiple cosmetic, medical and food applications. The cosmetic range of collagen is fully registered with the Vegan Society.

Collagen is a protein found in human and animal structural tissues such as bones, cartilage, skin and nails. Currently, most collagen is derived from animal tissue, but non-animal collagen is increasingly in demand. Produced from bacteria or yeast through a controlled fermentation-based process, non-animal collagen is easier to formulate and better absorbed by the skin than animal-derived collagen. Fermentation-based collagen also has low immunogenicity and batch-to-batch variability and is highly reproducible.

Evonik is a specialist in concepts for skin care, sun care, color cosmetics, hair care, skin cleansing, active ingredients, alternative preservation and product stabilization. Evonik's Nutrition & Care division is home to the company's biotechnology excellence center and uses fermentation technologies across various high growth markets.

Further Information

Find out more about Evonik Care Solutions <https://personal-care.evonik.com/>

Find out more about Jland Biotech <https://www.jland-biotech.com/>

Find out more about Evonik Venture Capital

<http://venturing.evonik.com/>

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.